Hepatocellular Carcinoma: From Genomic and Epigenomic Regulation to Drug Discovery
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 285
Special Issue Editors
Interests: hepatocellular carcinoma; drug discovery; genetic alteration; prostate cancer
Interests: drug screening and discovery; drug application of natural compounds; hepatocellular carcinoma; immunotherapy from natural compounds
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is one of the most common types of liver cancer and is responsible for a significant proportion of cancer-related deaths worldwide. Understanding the molecular mechanisms underlying HCC development and progression is crucial for the development of new diagnostic and therapeutic strategies. This Special Issue aims to gather original research articles, reviews, and perspectives related to the genomic and epigenomic regulation of HCC, including the identification of the key molecular mechanisms involved in the pathogenesis and progression of HCC. Furthermore, the Special Issue will also highlight the current state of the art in drug discovery for HCC, including novel targeted therapies and immunotherapies.
Potential topics of interest include, but are not limited to:
- Genomic and epigenomic profiling of HCC;
- Molecular mechanisms involved in HCC pathogenesis and progression;
- Biomarkers for early detection and prognosis of HCC;
- Targeted therapies for HCC;
- Immunotherapies for HCC;
- Drug-resistance mechanisms in HCC;
- Preclinical and clinical studies of HCC therapeutics
The goal of this Special Issue is to provide a comprehensive overview of the latest advances in the field of HCC research, which will be of interest to researchers, clinicians, and drug developers working in this area.
Dr. Feiyu Chen
Dr. Zhangfeng Zhong
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genomic and epigenomic modulation
- hepatic tumorigenesis signaling pathway
- in vitro models for studying HCC
- in vivo models for studying HCC, MRI, CT, and potential therapeutic strategies
